Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–32 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Withdrawn No phase listed Observational Accepts healthy volunteers

Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs

NCT01371045
Conditions
Acromegaly
Interventions
Oral Glucose Tolerance Test (OGTT)
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Neuroendocrine Tumors, Gastrointestinal Neoplasms, Carcinoid Tumors
Interventions
Lanreotide, Y-90 microspheres
Drug · Device
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Denver, Colorado • Kansas City, Missouri • Nashville, Tennessee
Conditions
Pancreatic Diseases
Interventions
Somatostatin analog
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide

NCT02270567
Conditions
Neuroendocrine Tumor, Carcinoid, Neuroendocrine Carcinoma
Interventions
NETest
Device
Lead sponsor
Wren Laboratories LLC
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Branford, Connecticut
Completed Phase 2 Interventional Results available

Pasireotide LAR in Severe Polycystic Liver Disease

NCT01670110
Conditions
Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease
Interventions
Pasireotide LAR, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Neuroendocrine Tumors
Interventions
Cabozantinib, Lu-177
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Acromegaly
Interventions
Somatuline Autogel (lanreotide acetate), Home administration
Drug · Behavioral
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
La Mesa, California • Los Angeles, California • Denver, Colorado + 8 more
Conditions
Thyroid Cancer
Interventions
68Ga-DOTA-TATE PET Scan, Amino acid infusions, 177Lu-DOTA-EB-TATE
Diagnostic Test · Other · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland